不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
30 例胃肠道自然杀伤/T 细胞淋巴瘤患者的临床特征、治疗及生存情况
英文原题：Clinical characteristics, treatment, and survival of 30 patients with gastrointestinal natural killer/T-cell lymphoma.
查看英文原题
Clinical characteristics, treatment, and survival of 30 patients with gastrointestinal natural killer/T-cell lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
即使在以天冬酰胺酶为基础的现代治疗策略时代，GI-ENKTL 的预后仍然很差。
研究思路结论见上方概要
背景
胃肠道是ENKTL第二常见的结外受累部位。本研究旨在探讨胃肠道ENKTL（GI-ENKTL）的临床病理特征、治疗模式、生存结局及预后。
方法
GI-ENKTL患者的临床数据从中国淋巴瘤协作组（CLCG）数据库中提取，并进行回顾性分析。
结果
共纳入30例患者，男女比例为4:1，中位年龄为42岁。29例患者接受了化疗，其中15例接受了以门冬酰胺酶为基础（ASP-based）的方案。此外，7例接受了手术，3例接受了放疗。整个队列的总体缓解率和完全缓解率分别为50.0%和30.0%，接受ASP-based方案治疗的患者分别为50.0%和37.5%，接受非ASP-based方案治疗的患者分别为50.0%和25.0%。中位随访时间为12.9个月，整个队列的1年总生存率为40.0%。对于早期患者，ASP-based方案相比非ASP-based方案获得了更优的1年无进展生存率（100.0% vs. 36.0%，p = .07）。然而，ASP-based方案并未改善晚期患者的生存。
展开英文摘要原文
BACKGROUND
The gastrointestinal (GI) tract is the second most frequent extranasal involvement site for ENKTL. This study aimed to explore the clinicopathological features, treatment models, survival outcomes, and prognosis of gastrointestinal ENKTL (GI-ENKTL).
METHODS
The clinical data of GI-ENKTL patients were extracted from the China Lymphoma Collaborative Group (CLCG) database and were analyzed retrospectively.
RESULTS
A total of 30 patients were enrolled, with a male/female ratio of 4:1 and a median age of 42 years. Twenty-nine patients received chemotherapy, of whom 15 patients received asparaginase-based (ASP-based) regimens. Moreover, seven received surgery and three received radiotherapy. The overall response an d complete remission rates were 50.0% and 30.0% for the whole cohort, 50.0% and 37.5% for patients treated with ASP-based regimens, and 50.0% and 25.0% for those treated with non-ASP-based regimens, respectively. The median follow-up was 12.9 months and the 1-year overall survival rate was 40.0% for the whole cohort. For those patients in an early stage, ASP-based regimens resulted in a superior 1-year progression-free survival rate compared to non-ASP-based regimens (100.0% vs. 36.0%, p = .07). However, ASP-based regimens did not improve survival in patients at an advanced stage.
CONCLUSION
GI-ENKTL still has a poor prognosis, even in the era of modern asparaginase-based treatment strategies.
论文信息
- 作者
- Liu JX、Liu X、Yang Y、Liu WP、Wang Y、He X、Zhang LL、Qu BL
- 单位
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.China
- 文献类型
- 非美国政府资助研究
- 期刊
- Cancer reports (Hoboken, N.J.)2023 May
- 原文标识
- PubMed 36919649 · DOI 10.1002/cnr2.1800
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →